What Лидент Бэби treats: main uses and benefits

This medication is applied across therapeutic domains involving acute or disruptive symptom patterns in the mouth, with a focus on temporary symptomatic relief. Its main use is to help ease the discomfort and pain associated with the process of primary tooth eruption (teething) in infants and young children.

The preparation is specifically used for managing symptoms associated with teething, which may assist in easing temporary distress and gum irritation. The symptomatic relief provided may assist in easing the overall symptom burden during periods of heightened discomfort.

Relief from Localized Oral Pain and Soreness

The gel is relevant for easing symptoms related to physical discomfort by addressing localized pain and soreness arising in the gum tissue. By addressing localized symptoms related to physical discomfort, it contributes to improved day-to-day comfort during symptomatic periods.

Soothing Gum Irritation and Inflammation

The product is applied in addressing symptoms related to inflammatory or irritative states of the gum tissue, helping to manage the manifestations of tenderness and irritation. This use may assist in addressing discomfort associated with irritation of the gum tissue, and is commonly applied in contexts marked by increased discomfort.

Support During Teething Episodes

As a non-systemic, topical treatment, the product is commonly used to help with symptoms associated with acute or episodic changes, such as a teething flare-up. It offers symptomatic relief that may help patients cope more steadily with difficult episodes, and is commonly used to help with symptoms that interfere with daily comfort.

Regulatory References

1. official regulatory information (Calgel dental gel)

Eligibility Scope: Official Regulatory Information

Official regulatory documentation defines eligibility for this topical gel through strict age limits and specific health exclusions.

Resulting Eligibility Structure

The medicinal product is absolutely contraindicated for infants below the locally specified minimum age, and for individuals with established hypersensitivity or hereditary fructose intolerance. Furthermore, regulatory authorities require that the product be used with caution in patients with liver, heart, or kidney impairment due to the potential for altered systemic exposure. This structured approach confines the use of the gel exclusively to the intended pediatric population under defined conditions.

Interactions with other medicines and products

The official interaction profile for this topical dental gel (containing Lidocaine Hydrochloride and Cetylpyridinium Chloride) is defined by the low systemic absorption of its active ingredients when used as directed.

Interaction scope

Interaction classifications (high-level)

Connection to the overall interaction profile

Regulatory documents explicitly state that no clinically significant drug-drug interactions are known for the topical gel. The profile is structured around the resulting low systemic interaction risk, focusing instead on two mandatory constraints: the prohibition against using other lidocaine-containing products concurrently and the constraint that co-administration with other medicinal products containing ethanol should be avoided.

Лидент Бэби utilizes the pharmacodynamic actions of lidocaine hydrochloride and cetylpyridinium chloride. Lidocaine, an amide-class local anesthetic, targets voltage-gated sodium channels (VGSCs) in neuronal membranes, specifically accumulating in the oral mucosal tissue upon topical application. The interaction is a non-competitive, use-dependent inhibition of these channels, predominantly targeting the alpha-subunits (e.g., NaV1.7, NaV1.8, NaV1.9). This inhibition prevents the influx of Na^+ ions necessary for the rapid depolarization phase of the action potential. The intracellular consequence is a stabilization of the neuronal cell membrane and a failure of impulse generation and propagation along the axon. At the system level, this localized modulation results in a transient, reversible block of sensory nerve signal transmission. Concurrently, cetylpyridinium chloride, a quaternary ammonium compound, acts as an antiseptic. Its molecular mechanism involves a general, non-specific interaction with microbial cell membranes. This interaction disrupts the permeability of the bacterial cell wall and cytoplasmic membrane, leading to the leakage of intracellular components, which culminates in bacterial cell lysis and death, providing a localized antimicrobial effect.

The administration of Лидент Бэби, a low-concentration gingival gel, is structured by a clear set of instructions. The preparation is designated for oromucosal use through topical administration directly to the gum tissue.

Administration Scope

The protocol defines the precise amount and frequency of use. For a single application, a pea-sized amount of gel, which corresponds to approximately 0.2 grams, is to be applied gently using a clean fingertip. The use of the gel is strictly limited in its repetition; a dose may be repeated only after a mandatory interval of 3 hours has passed. The instructions establish a firm maximum of 6 doses permitted within any 24-hour period, ensuring controlled exposure.

Age and Duration Constraints

The product's use is subject to specific age and duration constraints. The product is indicated for use in babies from the age of 5 months and should only be employed when non-pharmacological treatments have failed to provide adequate relief. Furthermore, the protocol mandates that treatment must be restricted to short-term use, not exceeding 7 consecutive days, and application must be ceased immediately once the symptoms have resolved. It is an explicit instruction that other products containing lidocaine must not be used concurrently.

Instruction Classifications

These instructions establish a precise, non-systemic administration protocol that governs the application amount, maximum frequency, and duration of use. The protocol mandates the topical route and defines strict numerical constraints—0.2 grams per dose, a 3-hour minimum interval, and a 6-dose maximum daily—which collectively structure the controlled and short-term nature of the product's use.

Research evidence / Overview of Studies for Лидент Бэби

This section summarizes the structure and scope of official research that has been conducted for topical gels containing the active ingredients in Лидент Бэби (Lidocaine Hydrochloride and Cetylpyridinium Chloride). This summary focuses only on the evidence landscape and does not offer any clinical advice or safety information.

Evidence for Symptomatic Relief of Teething Pain

The research base explored for topical gels containing lidocaine and cetylpyridinium chloride includes Randomized Controlled Trials (RCTs) and various systematic Literature Reviews. These studies were used in research exploring how symptoms change over time in conditions characterized by fluctuating or episodic manifestations, such as teething pain.

What the studies reported (neutral summary): Research has explored the efficacy of these topical agents for teething; however, the evidence is often described as limited and inconsistent by scientific reviews. Studies report how symptoms evolved in the observed populations during the short period immediately following the gel's application. Findings describe patterns observed in the studies related to subjective pain reporting and observed oral symptoms. The evidence contributes to understanding symptom patterns.

Study Endpoints and Measures Examined in Trials

The clinical trials that have been conducted focused on evaluating outcomes related to physical discomfort. Studies monitored patient-reported measures of perceived discomfort. Researchers focused on the assessment of pain intensity and reduction, as well as scoring systems for visible teething symptoms like gum swelling and redness. The studies explored measures of symptoms in infants and toddlers.

Scientific bodies note that some of the subjective endpoints used in earlier studies were not fully validated, which contributes to the limitations in the data.

What Is Still Uncertain About the Research for Лидент Бэби

Scientific literature consistently highlights several research limitations regarding topical gels for teething. The evidence base is considered limited due to a lack of high-quality, placebo-controlled trials specifically designed and executed for this indication. Certainty remains low regarding definitive efficacy due to challenges with study designs.

Furthermore, long-term outcomes are not fully established. There is limited information for long-term outcomes, and comparative evidence against other standard non-medicinal approaches for teething is limited in the regulatory research record. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Key Studies & References

1. Efficacy of treatments used to relieve signs and symptoms associated with teething: a systematic review

Common questions about Лидент Бэби (FAQ)

Q: Is this gel safe to use for pregnant or breastfeeding women?

Official regulatory documents indicate that the product is not recommended during pregnancy due to safety for the developing baby not being fully established. When breastfeeding, the official label notes that the product is generally considered compatible with lactation, as the active ingredient, lidocaine, is only excreted in breast milk in small amounts, and no adverse effects have been reported in breastfed infants at recommended therapeutic doses.

Q: What should I do if my baby uses more gel than recommended?

Official guidelines indicate that if an overdose is suspected, product use should be discontinued and a doctor or healthcare provider should be consulted immediately. Regulatory documents warn that using excessive amounts may lead to high levels of the anesthetic component in the blood, which carries a theoretical risk of toxic effects that could affect the central nervous system or heart.

Q: What common side effects should I look out for?

Official product information notes that adverse reactions have been reported, primarily related to the immune system and the application site. These include localized redness (erythema), dermatitis, and other hypersensitivity reactions. The official label states that the frequency of these reported side effects is 'Not known,' meaning their occurrence rate cannot be reliably estimated from available data.

Q: How long can I use Лидент Бэби continuously?

Regulatory guidelines specify that the product must not be used for more than seven consecutive days, as treatment is intended for short-term use only. The protocol also mandates that application must be ceased immediately once the symptoms have resolved.

Q: Does this gel interact with common baby medicines like paracetamol or ibuprofen?

Official regulatory documents explicitly state that no clinically significant drug-drug interactions are known for this topical gel. The only mandatory interaction restrictions focus on avoiding concurrent use with other products that contain lidocaine or other medicinal products that contain ethanol (alcohol).

Q: What does the cetylpyridinium chloride component do?

The preparation contains cetylpyridinium chloride in addition to lidocaine. This component is an active ingredient with known antiseptic properties, and it is included to provide a localized antimicrobial effect at the application site in the mouth.

Q: Can I still use this gel if my baby has a rare hereditary fructose intolerance?

Official product information states that the preparation is strictly contraindicated for infants with rare hereditary fructose intolerance. This is a mandatory restriction based on the official label due to the presence of specific excipients (inactive ingredients) used in the gel’s formulation.

How to Store and Dispose of Лидент Бэби?

The official storage and disposal guidelines for this Lidocaine/Cetylpyridinium Chloride dental gel are defined by regulatory documents to maintain product integrity and safety.

Official Storage Requirements

The product must not be stored above 25°C, ensuring the active components remain stable for the full shelf-life as defined in the labeling.

Official Disposal Protocol

Regulatory documents state that there are "No special requirements for disposal" for the unused or expired medicinal product. Patients should adhere to any general local waste management rules for non-hazardous pharmaceutical waste.